Lenalidomide Market Share to Reach $ 15.67 Billion Globally by 2032 at 4.7% CAGR

𝐋𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐎𝐯𝐞𝐫𝐯𝐢𝐞𝐰:

The lenalidomide market has experienced significant growth due to its effectiveness in treating hematological malignancies and its approval for multiple indications. As a targeted therapy, lenalidomide has shown promising results in clinical trials, leading to its widespread adoption in oncology practice. The market is driven by factors such as increasing cancer prevalence, expanding treatment indications, and advancements in lenalidomide-based therapies.

The global lenalidomide market size is expected to reach USD 15.67 billion by 2032, according to a new study by Polaris Market Research. The report "Lenalidomide Market Share, Size, Trends, Industry Analysis Report, By Type (5mg,10mg,15mg,25mg); By Application; By End-User; By Dosage; By Region; Segment Forecast, 2024 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The growth of lenalidomide is highly influenced by the increasing number of cancer cases worldwide. The higher efficiency of this drug in treating multiple myeloma, myelodysplastic syndromes, and lymphoma patients is anticipated to promote its demand in the marketplace. Pharmaceutical companies use Revlimid as a brand name in the marketing of lenalidomide.

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐨𝐟 𝐭𝐡𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 @ https://www.polarismarketresearch.com/industry-analysis/lenalidomide-market/request-for-sample

The rising initiatives by pharmaceutical companies to expand their brand coverage in the lenalidomide market are likely to stimulate the growth of the global market, as they can enhance the accessibility of medicine. For instance, in March 2023, Natco Pharma unveiled the additional strengths of Revlimid in its latest version with 2.5 mg and 20 mg strengths in the United States through its marketing agent, Teva Pharmaceuticals.

Furthermore, pharmaceutical firms are engaging in development activities related to lenalidomide, driving the expansion of the global market. According to the Start on Therapeutics report, STAR-LLD, the infusion of lower-dose lenalidomide into the blood was demonstrated to be the optimal treatment over Revlimid in some myeloma patients.

The increasing incidence of blood cancer is facilitating the need for drugs, including lenalidomide, in the marketplace, driven by its profound ability to treat the disease. According to the American Cancer Society 2023 Report, in the United States, there will be 609,820 deaths caused by cancer, and the estimated number of new cases is 1,958,310. This trend is emphasizing the need to enhance the accessibility of lenalidomide for patients.

Pharmaceutical firms are resolving patent issues associated with the production of lenalidomide with the settlements, contributing to the increased supply of this drug in the global market. For instance, in 2023, Sun Pharma received approval from the USFDA to market generic lenalidomide capsules in several strengths after entering into a settlement agreement with Celgene Corporation. With this, it can produce an unlimited quantity after January 2026 in the U.S., fueling the supply of this prominent cancer drug during the forecast period.

𝐆𝐫𝐨𝐰𝐭𝐡 𝐃𝐫𝐢𝐯𝐞𝐫𝐬:

𝐑𝐢𝐬𝐢𝐧𝐠 𝐂𝐚𝐧𝐜𝐞𝐫 𝐏𝐫𝐞𝐯𝐚𝐥𝐞𝐧𝐜𝐞:

The increasing incidence of hematological malignancies such as multiple myeloma, MDS, and mantle cell lymphoma drives the demand for lenalidomide. As cancer rates continue to rise globally, particularly among aging populations, there is a growing need for effective treatments like lenalidomide to manage these diseases and improve patient outcomes.

𝐄𝐱𝐩𝐚𝐧𝐝𝐢𝐧𝐠 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 𝐈𝐧𝐝𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:

Lenalidomide has received approval for multiple indications, including first-line and maintenance therapy for multiple myeloma, as well as treatment of MDS and mantle cell lymphoma. The expansion of lenalidomide's approved indications increases its market potential and broadens its usage across different patient populations, contributing to market growth.

𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐦𝐞𝐧𝐭𝐬 𝐢𝐧 𝐂𝐨𝐦𝐛𝐢𝐧𝐚𝐭𝐢𝐨𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬:

Ongoing research and clinical trials have focused on evaluating lenalidomide in combination with other drugs, such as proteasome inhibitors, monoclonal antibodies, and chemotherapy agents. Combination therapies involving lenalidomide have shown synergistic effects and improved outcomes in patients with hematological malignancies, driving demand for the drug and expanding its market opportunities.

𝐁𝐮𝐲 𝐭𝐡𝐢𝐬 𝐏𝐫𝐞𝐦𝐢𝐮𝐦 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: https://www.polarismarketresearch.com/buy/3315/2

𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧𝐬:

𝐌𝐮𝐥𝐭𝐢𝐩𝐥𝐞 𝐌𝐲𝐞𝐥𝐨𝐦𝐚:

Lenalidomide is a key treatment option for patients with multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. It is used as part of induction therapy, maintenance therapy following stem cell transplantation, and as a single-agent or combination therapy for relapsed or refractory disease. Lenalidomide-based regimens have demonstrated efficacy in improving response rates, delaying disease progression, and prolonging survival in multiple myeloma patients.

𝐌𝐲𝐞𝐥𝐨𝐝𝐲𝐬𝐩𝐥𝐚𝐬𝐭𝐢𝐜 𝐒𝐲𝐧𝐝𝐫𝐨𝐦𝐞𝐬 (𝐌𝐃𝐒):

Lenalidomide is also used in the treatment of MDS, a group of hematological disorders characterized by ineffective blood cell production. It is particularly beneficial for patients with low or intermediate-risk MDS associated with a deletion of chromosome 5q (del[5q]) abnormality. Lenalidomide helps improve blood cell counts, reduce transfusion dependence, and delay disease progression in patients with del(5q) MDS.

𝐌𝐚𝐧𝐭𝐥𝐞 𝐂𝐞𝐥𝐥 𝐋𝐲𝐦𝐩𝐡𝐨𝐦𝐚 (𝐌𝐂𝐋):

Lenalidomide has emerged as a treatment option for patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma characterized by the abnormal proliferation of B-cells. It is used as monotherapy or in combination with other agents for the treatment of relapsed or refractory MCL. Lenalidomide-based regimens have shown efficacy in inducing remissions, improving progression-free survival, and enhancing overall survival in MCL patients.

𝐋𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬

5mg capsules segment is anticipated to witness the highest growth in the coming years due to its flexibility.

Multiple myeloma segment accounted for the largest market share owing to the prominent performance of lenalidomide in treating multiple myeloma.

Hospitals segment is projected to experience a larger revenue share due to the rising number of cancer patients consulting hospitals.

APAC is projected to register the fastest growth attributable to the increasing number of patients with cancer-based medical complications.

The global players include Ablynx, Actiza, Celgene, Celltrion, Dexa Medical, Exova, LEO Pharma, Natco Pharma, & Toyama Chemical.

𝐏𝐨𝐥𝐚𝐫𝐢𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐡𝐚𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐭𝐡𝐞 𝐥𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞 𝐦𝐚𝐫𝐤𝐞𝐭 𝐫𝐞𝐩𝐨𝐫𝐭 𝐛𝐚𝐬𝐞𝐝 𝐨𝐧 𝐭𝐲𝐩𝐞, 𝐚𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧, 𝐞𝐧𝐝-𝐮𝐬𝐞𝐫, 𝐝𝐨𝐬𝐚𝐠𝐞, 𝐚𝐧𝐝 𝐫𝐞𝐠𝐢𝐨𝐧:

𝐋𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞, 𝐓𝐲𝐩𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞 - 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗 - 𝟐𝟎𝟑𝟐)
5mg Capsules
10mg Capsules
15mg Capsules
25mg Capsules

𝐋𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞, 𝐀𝐩𝐩𝐥𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞 - 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗 - 𝟐𝟎𝟑𝟐)

Multiple myeloma (MM)
Myelodysplastic syndromes (MDS)
Lymphoma
Others

𝐋𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞, 𝐄𝐧𝐝-𝐔𝐬𝐞𝐫 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞 - 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗 - 𝟐𝟎𝟑𝟐)

Hospitals
Cancer Treatment Centers
Research Institutes

𝐋𝐞𝐧𝐚𝐥𝐢𝐝𝐨𝐦𝐢𝐝𝐞, 𝐃𝐨𝐬𝐚𝐠𝐞 𝐎𝐮𝐭𝐥𝐨𝐨𝐤 (𝐑𝐞𝐯𝐞𝐧𝐮𝐞 - 𝐔𝐒𝐃 𝐁𝐢𝐥𝐥𝐢𝐨𝐧, 𝟐𝟎𝟏𝟗 - 𝟐𝟎𝟑𝟐)

Capsules
Tablets

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐮𝐬 𝐟𝐨𝐫 𝐒𝐩𝐞𝐜𝐢𝐚𝐥 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐚𝐧𝐝 𝐏𝐫𝐢𝐜𝐢𝐧𝐠 @ https://www.polarismarketresearch.com/industry-analysis/lenalidomide-market/request-for-discount-pricing

𝐓𝐡𝐞 𝐆𝐞𝐨𝐠𝐫𝐚𝐩𝐡𝐢𝐜𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬 𝐂𝐨𝐯𝐞𝐫𝐬 𝐅𝐨𝐥𝐥𝐨𝐰𝐢𝐧𝐠 𝐊𝐞𝐲 𝐑𝐞𝐠𝐢𝐨𝐧𝐬:

North America (United States, Canada, and Mexico)

Europe (Germany, France, United Kingdom, Russia, Italy, and the Rest of Europe)

Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and the rest of South America)

The Middle East and Africa (Saudi Arabia, United Arab Emirates, Egypt, South Africa, and the Rest of the Middle East and Africa)

𝐄𝐱𝐩𝐥𝐨𝐫𝐞 𝐌𝐨𝐫𝐞:

𝐎𝐫𝐠𝐚𝐧𝐢𝐜 𝐋𝐢𝐪𝐮𝐢𝐝 𝐒𝐨𝐚𝐩 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.linkedin.com/pulse/organic-liquid-soap-market-embracing-clean-sustainable-tn2jf

𝐐𝐮𝐢𝐥𝐥𝐚𝐢𝐚 𝐄𝐱𝐭𝐫𝐚𝐜𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.linkedin.com/pulse/quillaia-extracts-market-tapping-natures-bounty-natural-e9qgf

𝐑𝐞𝐚𝐝𝐲-𝐓𝐨-𝐃𝐫𝐢𝐧𝐤 𝐂𝐨𝐜𝐤𝐭𝐚𝐢𝐥𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.linkedin.com/pulse/ready-to-drink-cocktails-market-savoring-convenience-liquid-harne-j6hpf

𝐏𝐫𝐨𝐛𝐢𝐨𝐭𝐢𝐜 𝐂𝐨𝐬𝐦𝐞𝐭𝐢𝐜 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 𝐌𝐚𝐫𝐤𝐞𝐭: https://www.linkedin.com/pulse/probiotic-cosmetic-products-market-nurturing-dkxuf

𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐈𝐧𝐟𝐨:

Polaris Market Research
30 Wall Street, 8th Floor,
New York City, NY 10005,
United States
Phone:+1-929 297-9727
Email: sales@polarismarketresearch.com

𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defence, among different ventures present globally.

This release was published on openPR.